OncoTherapy Science, Inc., Carna Biosciences, And CrystalGenomics To Collaborate In Development Of Low-Molecular Drug For Cancer
2/1/2006 2:18:22 PM
Tokyo, Feb 1, 2006 (JCN) - OncoTherapy Science (OTS) announced on February 1 that it has signed a joint research agreement with Carna Biosciences (CARNA) and CrystalGenomics (CG). The three companies will collaborate in searching low-molecular compounds that inhibit the activities of two different cancer-specific protein kinases possessed by OTS. Specifically, CARNA will be in charge of protein expression, assay formulation and screening while CG will handle virtual screening of compounds, compound library creation and X-ray crystallographic analysis.